Group 1: Company Performance and Stock Price - The company's stock price has been affected by industry cycles, leading to volatility, and investors are encouraged to view this rationally [4][18] - The company reported a significant asset impairment provision of RMB 89.23 million for 2025, impacting current performance [18] - The semiconductor precision tools business of the subsidiary Jiangsu Sanjing continues to grow, with revenue increasing year-on-year [18] Group 2: Investor Relations and Communication - The company emphasizes the importance of investor relations and has committed to improving communication and response times to investor inquiries [3][12] - The company adheres to information disclosure regulations and aims to enhance the management of interactive platforms to protect the rights of small investors [3][12] Group 3: Research and Development Focus - The 2026 R&D investment will focus on improving product quality and core competitiveness, particularly in diamond wire and diamond grinding wheels [5][9] - The company plans to enhance the stability and cutting power of its products while advancing the mass production of ultra-fine tungsten wire [5] Group 4: Market Strategy and Future Plans - The company aims to expand its market presence by focusing on high-value segments and enhancing the synergy between sales, marketing, and research [11][13] - Future developments will include a focus on semiconductor materials and potential expansion into the photovoltaic sector, depending on market demand [20][30] Group 5: Financial Health and Risk Management - The company maintains a stable cash flow and does not foresee liquidity risks [13] - The impact of fluctuations in the photovoltaic industry on the diamond wire segment is acknowledged, as it is a major application area [10]

Group 1: Financial Performance - In 2025, the company achieved a revenue of 110.78 billion CNY, representing a year-on-year growth of 25.70% [2] - The net profit attributable to shareholders was 23.93 billion CNY, with a year-on-year increase of 18.99% [2] - The tire mold business generated a revenue of 55.09 billion CNY, up 18.44% year-on-year, with a gross margin of 39.98%, an increase of 0.39 percentage points [2] Group 2: Business Segments - Large component machinery products achieved a revenue of 39.64 billion CNY, reflecting a year-on-year growth of 18.97% [4] - The CNC machine tool business saw a significant revenue increase of 142.59%, reaching 9.68 billion CNY [2][5] - The sulfur machine business generated over 400 million CNY in revenue, with higher sales in the second half of the year compared to the first half [4] Group 3: Cost and Expenses - Management, sales, and R&D expenses remained stable as a percentage of revenue compared to Q4 2024, while R&D expenses increased due to the development phase of the machine tool business [3] - Financial expenses were influenced by exchange rate fluctuations [3] Group 4: Inventory and Production - The tire mold business operates on an order-based production model, resulting in inventory growth aligned with business expansion [3] - The CNC machine tool segment maintains some inventory for regular products due to long production cycles [3] Group 5: Market Dynamics - Domestic customer demand for tire molds has increased, with the ratio of domestic to foreign customers nearing 1:1 by the end of 2025 [3] - The wind power market has experienced price volatility, with prices adjusting according to market conditions [3] Group 6: Future Outlook - The company plans significant capital expenditures in 2025, including a 65,000-ton casting expansion project and capacity enhancements in Thailand and Mexico [3] - The development of the sulfur machine business in 2026 is expected to be positive, contingent on market demand and order fluctuations [4]

| | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | 动类别 | □现场参观 | | □其他 | | | 活动参与人员 | 1、参与公司 2025 年度网上业绩说明会活动的投资者 | | | 2、上市公司接待人员：董事长兼总裁李葛丰先生、董事兼财 | | | 务总监谢伟光先生、独立董事李建林先生、董事会秘书黄幼平 | | 女士 | | | 2026 时间 | 年 4 月 1 日（星期三）15:00-17:00 | | | 深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn） | | 地点 | "云访谈"栏目 | | 形式 | 网络文字交流 | | | 1、公司在储能技术方面有哪些规划和布局方向？ 答：公司高度重视技术创新，持续加大研发投入，2026 年计 | | | 划重点布局高性能、高安全、高可靠的储能系统产品，适配储 | | | 能规模化并网、集群化调度等行业发展趋势；聚焦算力数据中 | | 交流内容及具 | 心核心能源需求，适时开展高效电能转换、能源智能协同等方 | ...

Group 1: Company Overview and Strategic Partnerships - The company has established a strategic partnership with Defo Capital, aiming to become a major platform for integrating past investment businesses in the health sector, with a goal of "building China's DSM" [2][3] - The collaboration with DSM-Firmenich has been ongoing since 2024, focusing on achieving annual procurement targets and strengthening revenue foundations through mutual trust and business empowerment [4][5] Group 2: Product Development and Innovations - The company has developed a synthetic biology business strategy since 2022, focusing on enhancing production efficiency and reducing costs, with key products including the steviol glycoside RM series and biopolysaccharides [3][4] - The steviol glycoside RM2 product received FDA GRAS certification last year, with domestic certification pending final review, highlighting its advantages in sweetness, taste, solubility, and cost control [3] - Biopolysaccharides have been industrialized and are currently applied in the daily chemical sector, with ongoing efforts to obtain relevant certifications [3] Group 3: Manufacturing and Operational Enhancements - The company has upgraded its Indiana plant to a comprehensive plant extraction facility, focusing on brand raw materials and ensuring local resource utilization to enhance market competitiveness [5][6] - Future capital expenditures are expected to be minimal as the company shifts focus to operational efficiency and market expansion, particularly in the stevia extraction and synthetic biology sectors [6] Group 4: Market Trends and Regulatory Environment - Over 100 countries have implemented sugar tax policies, indicating a global trend towards health consciousness and diabetes management, which may positively impact the company's natural sweetener business [7] - The company is monitoring developments in the CBD market, with recent positive signals from U.S. policies regarding CBD inclusion in healthcare plans, while emphasizing the need for clear regulatory standards [7]

Group 1: Event Overview - The investor relations activity took place from February 26 to March 26, 2026 [2] - The event was held at the New Industry Biomedical Building, located at 23 Jinxiu East Road, Jinsha Community, Pingshan District, Shenzhen [2] - A total of 29 institutions and 37 participants attended the event [2] Group 2: Participants - Notable participants included major asset management firms such as Fidelity Investments, T. Rowe Price Associates, and J.P. Morgan Investment Management [3] - The complete list of participating institutions is available in the attached document [4] Group 3: Company Representatives - The event featured company representatives including Zhang Lei, the Deputy General Manager and Secretary of the Board, and Lü Yuning, the Head of Investor Relations [2] - No new major interactive content was introduced beyond previously disclosed investor relations activities [2]

Group 1: Acquisition Overview - The company fully acquires Jizhi Intelligent to enter the core track of voice AI, which is at the intersection of AI and the intelligent voice market, with clear commercial viability and scalability [2][3] - The acquisition is a cash transaction, with a performance commitment of a cumulative net profit of no less than 84 million yuan (average of 28 million yuan per year) from 2026 to 2028 [3][4] Group 2: Strategic Value and Synergy - The acquisition leverages over 20 years of resources in telecommunications, finance, and state-owned enterprises, enhancing Jizhi Intelligent's scalability [3][4] - Jizhi Intelligent complements the company's AI voice capabilities, integrating into the "1+1+N" AI strategic system, aiming to become a leader in the AI voice segment [3][4] Group 3: Business Model and Orders - Jizhi Intelligent's revenue model is primarily based on a revenue-sharing model, with a high repurchase rate of nearly 100% for project-based large model training [4][5] - The company has a robust order reserve and optimistic overall order situation [4] Group 4: Market Expansion and Collaboration - The acquisition allows for cross-selling and resource sharing between Jizhi Intelligent's existing clients and the company's customer base [4][7] - Specific scenarios for implementation include smart outbound calls, smart customer service, and multilingual AI customer service in overseas markets [7][8] Group 5: Competitive Landscape and Future Outlook - The domestic AI voice intelligent agent market is competitive, with Jizhi Intelligent positioned among the top players due to its strong technology and financial performance [8][9] - The company aims to maintain its competitive edge through self-developed vertical large models and a solid data barrier, ensuring continued leadership in the industry [9][10]

Group 1: Company Overview and Core Business - The company is a professional R&D and manufacturing service base for industrial steam turbines in China, contributing significantly to the country's industrial development and economic security [2][4]. - It has over 60 years of experience in industrial steam turbines, with applications in various sectors including petrochemicals, metallurgy, and renewable energy [2][4]. - The company has established a complete industrial system for gas turbines, covering R&D, manufacturing, testing, and engineering services since entering the gas turbine market in 2005 [3][6]. Group 2: Industrial Steam Turbine Development - The development of industrial steam turbines can be divided into four stages: exploration (1958-1975), technology absorption (1975-1990), self-design and manufacturing (1990-2000), and independent innovation (2000-present) [4]. - The products are customized with high reliability, efficiency, and adaptability, primarily serving industrial power generation and drive applications [4][5]. - The competitive landscape includes high-end industrial drive sectors competing with international brands like Siemens and Mitsubishi, while the power generation sector faces intense domestic competition [4][5]. Group 3: Gas Turbine Business and Innovations - The gas turbine business is a core focus for the company's strategic transformation during the 14th and 15th Five-Year Plans [6]. - The company has collaborated with Mitsubishi and Siemens to enhance its gas turbine offerings, delivering over 50 units of the SGT series to the market [6][7]. - The first self-developed gas turbine prototype is expected to be completed in 2024, with full-load testing in mid-2025, achieving performance metrics that meet domestic advanced standards [6][7]. Group 4: Project Developments and Market Expansion - The Lianyungang demonstration project is crucial for the application of the company's self-developed gas turbines, with significant milestones achieved in project registration and design [7]. - The company is expanding its overseas market presence, focusing on regions along the Belt and Road Initiative, primarily through partnerships with domestic contractors [9]. - The company emphasizes maintaining control over its supply chain for core components of gas turbines to mitigate risks from external environmental changes [9]. Group 5: Financial Policies and Incentives - The company implements a profit distribution policy that prioritizes cash dividends, aiming to distribute at least 30% of the average distributable profit over the last three years every three years [10]. - There are plans for a stock incentive program to align shareholder and team interests, with various incentive tools being explored [10].

Financial Performance - The company achieved a revenue of 7.031 billion CNY, a year-on-year increase of 27% [1] - Net profit attributable to shareholders reached 307 million CNY, up 233% year-on-year [1] - Basic earnings per share were 0.36 CNY, reflecting a 227% increase [1] - Product sales grew by 21%, marking the eighth consecutive year of growth [1] Production Capacity - Total production capacity is 30,000 tons per year, with a utilization rate of 84% for the Yantai base and 88% for the Nantong base [2] - The company plans to add 6,000 tons of capacity at the Nantong base, subject to market conditions [2] Application Fields - High-performance NdFeB permanent magnetic materials are primarily used in high-end applications such as smart connected new energy vehicles, humanoid robots, and energy-saving appliances [1] - The company has covered the top 10 international automotive brands and the top 5 domestic brands in the energy-saving and new energy vehicle sector, with over 8 million sets of products used in electric motors for these vehicles, a growth of over 40% [2] Technological Advancements - The company is advancing its no-heavy rare earth technology, integrating machine learning and AI to enhance product performance [5] - R&D investment exceeded 400 million CNY, a 22% increase, with a total of 335 patents, including 93 newly published and 59 newly authorized [5] Export Business - Export revenue increased by 43% due to stable approvals for export licenses and growing market acceptance of no-heavy rare earth magnets [6] - The company has effectively adapted to export policy changes, ensuring stable overseas operations [6] Commercial Ecosystem - The company has established a robust commercial ecosystem, with the automotive market as the core, particularly in energy-saving and new energy vehicles [4] - It is recognized as a national champion in manufacturing high-performance sintered NdFeB magnets for new energy vehicles [4]

Financial Performance - In 2025, the company achieved a revenue of CNY 14.095 billion, representing a year-on-year growth of 14.8% [2] - Adjusted net profit attributable to shareholders was CNY 1.816 billion, up 13.0% year-on-year [2] - The net profit attributable to shareholders decreased by 7.2% to CNY 1.664 billion, primarily due to significant investment gains from the disposal of PROTEOLOGIX shares in 2024 [2] Business Segments - Laboratory services generated revenue of CNY 8.159 billion, with a gross margin of 44.7%, an increase of 0.3 percentage points year-on-year [3] - Small molecule CDMO services reported revenue of CNY 3.483 billion, growing by 16.5%, with a gross margin of 33.8%, up 0.7 percentage points [3] - Clinical research services earned CNY 1.957 billion, reflecting a growth of 7.1% [3] - Large molecule and CGT services achieved revenue of CNY 475 million, also growing by 16.5% [3] Client and Project Growth - The company added over 950 new clients in 2025, bringing the total active clients to over 3,300 [3] - The company participated in 887 global new drug discovery projects, an increase from 2024 [3] - In CMC services, the company was involved in 1,102 projects, including 34 commercial and validation projects, 47 Phase III projects, 271 Phase I/II projects, and 750 preclinical projects [3] Strategic Developments - A strategic cooperation agreement was signed in Q1 2026 with a major international pharmaceutical company for commercial production services of an oral small molecule GLP-1 receptor agonist [3] - The company has established 28 R&D centers and production bases globally, enhancing its integrated R&D and production capabilities [3] Future Outlook - The company expects steady growth in 2026, with new order momentum continuing [4] - Revenue growth in small molecule CDMO services is anticipated to outpace overall company revenue growth, with improved gross margins expected [4] - Clinical research services are projected to maintain growth in 2026 [4]

Group 1: Financial Performance - Revenue reached RMB 14,095 million, with a year-over-year growth of 14.8% [14] - Non-IFRS net profit was RMB 1,816 million, reflecting a year-over-year growth of 13.0% [14] - Net profit declined to RMB 1,664 million, a year-over-year decrease of 7.2% [14] - Revenue from the top 20 multinational corporations (MNCs) grew by 29.4% [14] Group 2: Customer and Market Expansion - Over 950 new customers acquired, totaling over 3,300 active customers, including all top 20 MNCs [15] - Revenue from China entities grew by 15.0%, while overseas subsidiaries saw a growth of 13.8% [21] - New purchase orders (POs) increased by 14% year-over-year [14] Group 3: Operational Highlights - 28 R&D and manufacturing facilities across China, the UK, the US, and Singapore [15] - 887 drug discovery projects currently in progress [16] - 1,397 clinical research organization (CRO) projects, including 125 in Phase III [16] Group 4: Future Outlook - Expected revenue growth of 12-18% year-over-year in 2026 [45] - Continued development of an end-to-end, fully integrated services platform [45] - Focus on advancing the contract development and manufacturing organization (CDMO) business model and integrating AI and automation [45] Group 5: ESG and Sustainability - Achieved an MSCI ESG rating of AA and recognized as a low-risk company by Sustainalytics [23] - Joined the United Nations Global Compact (UNGC) and received the EcoVadis Silver Prize [24]